Pulmonary Embolism Drugs Market Analysis

  • Report ID: 3400
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Pulmonary Embolism Drugs Market Analysis

Drug Class (Thrombolytics, Thrombosis, Heparins, Thrombin Inhibitors)

The global pulmonary embolism drugs market is segmented and analyzed for demand and supply by drug class into thrombolytics, thrombosis, heparins, thrombin inhibitors, and others. Out of these types of drug classes, the thrombosis segment is estimated to gain the largest market share in the year 2037. Thrombosis is a medical condition that is mainly caused by a lump of thick blood clots that forms in a blood vessel in the heart. Venous thrombosis is observed to be quite prevalent across the globe which is estimated to hike the market growth over the forecast period. For instance, it was expected that every year, in every 1000, 1 of them suffer from venous thrombosis. The occurrence rate of thrombosis rises after the age of 45 and is quite higher in men than women. The risk factors of thrombosis include immobility, hospitalization, trauma, pregnancy, and others.

Distribution Channel (Hospital Pharmacy, Drug Store, Online Pharmacy)

The global pulmonary embolism drugs market is also segmented and analyzed for demand and supply by distribution channel into hospital pharmacy, drug store, online pharmacy, and others. Amongst these segments, the hospital pharmacies segment is expected to garner a significant share in the year 2037. Hospitals are noticed to have luxury medical services in a single place. A huge staff of medical professionals is available to provide healthcare services 24/7. Furthermore, every nation is observed to spend a significant amount of money to develop hospital infrastructures to provide better medical services. The growth in the number of hospitals across the globe is anticipated to be backed by increasing income, population demographics, growing health awareness, and others. For instance, in India, the number of private hospitals was estimated to be around 40,000 while the number of public hospitals was anticipated to be nearly 25,000 in 2019.

Our in-depth analysis of the global market includes the following segments:

           By Drug Class

  • Thrombolytics
  • Thrombosis
  • Heparins
  • Thrombin Inhibitors
  • Others

 

          By Distribution Channel

  • Hospital Pharmacy
  • Drug Store
  • Online Pharmacy
  • Others
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3400
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of pulmonary embolism drugs is estimated at USD 1.84 billion.

The pulmonary embolism drugs market size was valued at USD 1.76 billion in 2024 and is set to cross USD 3.85 billion by the end of 2037, expanding at more than 6.1% CAGR during the forecast period i.e., between 2025-2037. Growing incidences of heart failure and increasing prevalence of pulmonary embolism (PE) will boost the market growth.

North American region will hold largest industry share by 2037, driven by rising healthcare expenditure backed by escalating government spending to develop healthcare services.

The major players in the market include Janssen Global Services, LLC, Novartis AG, Pfizer Inc., Sanofi S.A., Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Siemens Healthcare GmbH, Baxter International Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample